These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 12908369

  • 1. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
    Simoncini T, Mannella P, Genazzani AR.
    Recenti Prog Med; 2003 Feb; 94(2):51-6. PubMed ID: 12908369
    [Abstract] [Full Text] [Related]

  • 2. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
    Kozakiewicz K, Wycisk A.
    Wiad Lek; 2006 Feb; 59(5-6):377-82. PubMed ID: 17017486
    [Abstract] [Full Text] [Related]

  • 3. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM, Fini M.
    Int J Fertil Womens Med; 2001 Feb; 46(5):248-56. PubMed ID: 11720197
    [Abstract] [Full Text] [Related]

  • 4. Raloxifene: bone and cardiovascular effects.
    Francucci CM, Romagni P, Boscaro M.
    J Endocrinol Invest; 2005 Feb; 28(10 Suppl):85-9. PubMed ID: 16550730
    [Abstract] [Full Text] [Related]

  • 5. [SERM--selective estrogen receptor modulators].
    Kønig KB, Eiken PA, Schwarz P.
    Ugeskr Laeger; 2001 Apr 09; 163(15):2129-33. PubMed ID: 11332210
    [Abstract] [Full Text] [Related]

  • 6. Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women.
    Klein KP, Herrington DM.
    Medscape Womens Health; 2002 Apr 09; 7(5):2. PubMed ID: 12466731
    [No Abstract] [Full Text] [Related]

  • 7. Cardiovascular effects of raloxifene: the arterial and venous systems.
    Blumenthal RS, Baranowski B, Dowsett SA.
    Am Heart J; 2004 May 09; 147(5):783-9. PubMed ID: 15131531
    [Abstract] [Full Text] [Related]

  • 8. Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective.
    Mobasseri S, Liebson PR, Klein LW.
    Cardiol Rev; 2004 May 09; 12(6):287-98. PubMed ID: 15476565
    [Abstract] [Full Text] [Related]

  • 9. [An alternative to postmenopausal Hormone Replacement Therapy? Selective Estrogens Receptors Modulators (SERMs)].
    Tinelli A, Perrone A, Tinelli FG.
    Minerva Ginecol; 2001 Apr 09; 53(2):127-35. PubMed ID: 11319506
    [Abstract] [Full Text] [Related]

  • 10. [Raloxifene: a selective modulator of estrogen receptors].
    van den Brûle FA, Kalbus MF, Gaspard UJ.
    J Gynecol Obstet Biol Reprod (Paris); 1999 Dec 09; 28(8):788-99. PubMed ID: 10635481
    [Abstract] [Full Text] [Related]

  • 11. [Hormone replacement therapy and cardiovascular prevention. Where are we now?].
    Lerman J, Siseles N.
    Medicina (B Aires); 2008 Dec 09; 68(3):251-7. PubMed ID: 18689159
    [Abstract] [Full Text] [Related]

  • 12. Raloxifene, tamoxifen and vascular tone.
    Leung FP, Tsang SY, Wong CM, Yung LM, Chan YC, Leung HS, Yao X, Huang Y.
    Clin Exp Pharmacol Physiol; 2007 Aug 09; 34(8):809-13. PubMed ID: 17600563
    [Abstract] [Full Text] [Related]

  • 13. [Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated].
    Emons G, Westphalen S.
    MMW Fortschr Med; 2002 Feb 28; 144(9):30-3. PubMed ID: 11921648
    [Abstract] [Full Text] [Related]

  • 14. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T, Mizunuma H.
    Clin Calcium; 2004 Oct 28; 14(10):81-4. PubMed ID: 15577136
    [Abstract] [Full Text] [Related]

  • 15. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV, Khalil RA.
    Expert Rev Cardiovasc Ther; 2007 Jul 28; 5(4):777-89. PubMed ID: 17605655
    [Abstract] [Full Text] [Related]

  • 16. [Raloxifene hydrochloride].
    Itabashi A.
    Nihon Rinsho; 2004 Feb 28; 62 Suppl 2():528-35. PubMed ID: 15035185
    [No Abstract] [Full Text] [Related]

  • 17. The controversy over estrogen replacement therapy: an update on clinical trials.
    Gnatuk CL.
    Curr Womens Health Rep; 2002 Apr 28; 2(2):89-94. PubMed ID: 12116607
    [Abstract] [Full Text] [Related]

  • 18. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M.
    Clin Calcium; 2004 Oct 28; 14(10):105-10. PubMed ID: 15577140
    [Abstract] [Full Text] [Related]

  • 19. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H.
    Clin Calcium; 2004 Oct 28; 14(10):73-80. PubMed ID: 15577135
    [Abstract] [Full Text] [Related]

  • 20. Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma.
    Diamanti-Kandarakis E, Sykiotis GP, Papavassiliou AG.
    Cancer; 2003 Jan 01; 97(1):12-20. PubMed ID: 12491500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.